Hepatitis Monthly

Published by: Kowsar

Protective Effects of Adenosine Receptor Agonist in a Cirrhotic Liver Resection Model

Emil Iskandarov 1 , Pramod Kadaba Srinivasan 2 , * , Wang Xin 3 , Christian Bleilevens 4 , Mamdouh Afify 2 , Astrit Hamza 5 , Lai Wei 3 , Koichiro Hata 6 , Boyukkishi Agayev 1 and Rene Tolba 2
Authors Information
1 Department of Hepato-biliary and Pancreas Surgery, Scientific Center of Surgery named after academician M.A.Topchubashov, Baku, Azerbaijan
2 Institute for Laboratory Animal Science and Experimental Surgery, University Hospital, RWTH Aachen University, Aachen, Germany
3 Tongji Hospital, Tongji Medical College, Department of Surgery, Division of Transplantation, Wuhan, China
4 Department of Anaesthesiology, University Hospital, RWTH Aachen University, Aachen, Germany
5 Department of Abdominal Surgery, University Clinical Center of Kosovo, Prishtina, Kosovo
6 Department of Hepatobiliary, Pancreas and Transplant Surgery, Kyoto University, Yoshidahonmachi, Sakyo Ward, Kyoto, Japan
Article information
  • Hepatitis Monthly: August 01, 2016, 16 (8); e36821
  • Published Online: July 24, 2016
  • Article Type: Research Article
  • Received: February 2, 2016
  • Revised: March 7, 2016
  • Accepted: June 22, 2016
  • DOI: 10.5812/hepatmon.36821

To Cite: Iskandarov E, Kadaba Srinivasan P, Xin W, Bleilevens C, Afify M, et al. Protective Effects of Adenosine Receptor Agonist in a Cirrhotic Liver Resection Model, Hepat Mon. 2016 ; 16(8):e36821. doi: 10.5812/hepatmon.36821.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in europe: A review of available epidemiological data. J Hepatol. 2013; 58(3): 593-608
  • 2. Ruzzenente A, Valdegamberi A, Campagnaro T, Conci S, Pachera S, Iacono C, et al. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated? World J Gastroenterol. 2011; 17(46): 5083-8[DOI][PubMed]
  • 3. Hamza AR, Krasniqi AS, Srinivasan PK, Afify M, Bleilevens C, Klinge U, et al. Gut-liver axis improves with meloxicam treatment after cirrhotic liver resection. World J Gastroenterol. 2014; 20(40): 14841-54[DOI][PubMed]
  • 4. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008; 48 Suppl 1-37[DOI][PubMed]
  • 5. Mastron JK, Siveen KS, Sethi G, Bishayee A. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review. Anticancer Drugs. 2015; 26(5): 475-86[DOI][PubMed]
  • 6. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001; 414(6866): 916-20[DOI][PubMed]
  • 7. Brown RM, Short JL. Adenosine A(2A) receptors and their role in drug addiction. J Pharm Pharmacol. 2008; 60(11): 1409-30[DOI][PubMed]
  • 8. Cunha RA, Ferre S, Vaugeois JM, Chen JF. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des. 2008; 14(15): 1512-24[PubMed]
  • 9. Mingote S, Font L, Farrar AM, Vontell R, Worden LT, Stopper CM, et al. Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway. J Neurosci. 2008; 28(36): 9037-46[DOI][PubMed]
  • 10. Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Yee H, et al. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol. 2006; 148(8): 1144-55[DOI][PubMed]
  • 11. Hasko G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol. 2008; 83(3): 447-55[DOI][PubMed]
  • 12. Reinstein LJ, Lichtman SN, Currin RT, Wang J, Thurman RG, Lemasters JJ. Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A2 receptors on rat Kupffer cells. Hepatology. 1994; 19(6): 1445-52[PubMed]
  • 13. Lesurtel M, Lehmann K, de Rougemont O, Clavien PA. Clamping techniques and protecting strategies in liver surgery. HPB (Oxford). 2009; 11(4): 290-5[DOI][PubMed]
  • 14. Gurusamy KS, Gonzalez HD, Davidson BR. Current protective strategies in liver surgery. World J Gastroenterol. 2010; 16(48): 6098-103[PubMed]
  • 15. Carini R, De Cesaris MG, Splendore R, Vay D, Domenicotti C, Nitti MP, et al. Signal pathway involved in the development of hypoxic preconditioning in rat hepatocytes. Hepatology. 2001; 33(1): 131-9[DOI][PubMed]
  • 16. Carini R, Grazia De Cesaris M, Splendore R, Baldanzi G, Nitti MP, Alchera E, et al. Role of phosphatidylinositol 3-kinase in the development of hepatocyte preconditioning. Gastroenterology. 2004; 127(3): 914-23[PubMed]
  • 17. Dal Ponte C, Alchera E, Follenzi A, Imarisio C, Prat M, Albano E, et al. Pharmacological postconditioning protects against hepatic ischemia/reperfusion injury. Liver Transpl. 2011; 17(4): 474-82[DOI][PubMed]
  • 18. Peralta C, Hotter G, Closa D, Prats N, Xaus C, Gelpi E, et al. The protective role of adenosine in inducing nitric oxide synthesis in rat liver ischemia preconditioning is mediated by activation of adenosine A2 receptors. Hepatology. 1999; 29(1): 126-32[DOI][PubMed]
  • 19. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014; 12: 145[DOI][PubMed]
  • 20. Peralta C, Serafin A, Fernandez-Zabalegui L, Wu ZY, Rosello-Catafau J. Liver ischemic preconditioning: a new strategy for the prevention of ischemia-reperfusion injury. Transplant Proc. 2003; 35(5): 1800-2[PubMed]
  • 21. Schmidt R. Hepatic organ protection: from basic science to clinical practice. World J Gastroenterol. 2010; 16(48): 6044-5[PubMed]
  • 22. Hilmi I, Horton CN, Planinsic RM, Sakai T, Nicolau-Raducu R, Damian D, et al. The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation. Liver Transpl. 2008; 14(4): 504-8[DOI][PubMed]
  • 23. Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation--from bench to bedside. Nat Rev Gastroenterol Hepatol. 2013; 10(2): 79-89[DOI][PubMed]
  • 24. Alchera E, Dal Ponte C, Imarisio C, Albano E, Carini R. Molecular mechanisms of liver preconditioning. World J Gastroenterol. 2010; 16(48): 6058-67[PubMed]
  • 25. Ben-Ari Z, Pappo O, Sulkes J, Cheporko Y, Vidne BA, Hochhauser E. Effect of adenosine A2A receptor agonist (CGS) on ischemia/reperfusion injury in isolated rat liver. Apoptosis. 2005; 10(5): 955-62[DOI][PubMed]
  • 26. Harada N, Okajima K, Murakami K, Usune S, Sato C, Ohshima K, et al. Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J Pharmacol Exp Ther. 2000; 294(3): 1034-42[PubMed]
  • 27. Mandili G, Alchera E, Merlin S, Imarisio C, Chandrashekar BR, Riganti C, et al. Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2aR stimulation. J Hepatol. 2015; 62(3): 573-80[DOI][PubMed]
  • 28. Nakayama H, Yamamoto Y, Kume M, Yamagami K, Yamamoto H, Kimoto S, et al. Pharmacologic stimulation of adenosine A2 receptor supplants ischemic preconditioning in providing ischemic tolerance in rat livers. Surgery. 1999; 126(5): 945-54[PubMed]
  • 29. Tang LM, Wang YP, Wang K, Pu LY, Zhang F, Li XC, et al. Protective effect of adenosine A2A receptor activation in small-for-size liver transplantation. Transpl Int. 2007; 20(1): 93-101[DOI][PubMed]
  • 30. Fredholm BB, I. Jzerman AP , Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001; 53(4): 527-52[PubMed]
  • 31. Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, Chen JF, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest. 2003; 112(6): 883-91[DOI][PubMed]
  • 32. Mathie RT, Alexander B, Ralevic V, Burnstock G. Adenosine-induced dilatation of the rabbit hepatic arterial bed is mediated by A2-purinoceptors. Br J Pharmacol. 1991; 103(1): 1103-7[PubMed]
  • 33. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998; 50(3): 413-92[PubMed]
  • 34. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014; 20(23): 7312-24[DOI][PubMed]
  • 35. Minor T, Akbar S, Yamamoto Y. Adenosine a2 receptor stimulation protects the predamaged liver from cold preservation through activation of cyclic adenosine monophosphate–protein kinase a pathway. Liver Transplantation. 2000; 6(2): 196-200
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments